Humana (HUM)
(Delayed Data from NYSE)
$387.38 USD
-1.51 (-0.39%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $387.35 -0.03 (-0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$387.38 USD
-1.51 (-0.39%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $387.35 -0.03 (-0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
Zacks News
Select Medical's (SEM) Unit Begins IPO Roadshow for 22.5M Shares
by Zacks Equity Research
Select Medical's (SEM) subsidiary, Concentra, starts roadshow for IPO of 22.5 million shares, aiming to list on the NYSE under ticker "CON" with an expected price range of $23-$26 per share.
UnitedHealth Group (UNH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 2.26% and 0.15%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth (UNH) Pre-Q2 Earnings: Healthy Buy or a Wait-&-See?
by Kaibalya Pravo Dey
UnitedHealth's (UNH) second-quarter earnings are likely to have benefited from higher premiums, driven by the expansion of its commercial membership base.
Company News for Jul 5, 2024
by Zacks Equity Research
Companies In The News Are: STZ, PARA, HUM, MSFT.
Humana (HUM) Ties Up With PsychArmor for Better Veteran Care
by Zacks Equity Research
Humana's (HUM) subsidiaries team up with PsychArmor to enhance veteran care, offering specialized training at 23 senior primary care centers in Texas, thereby attracting more members of the targeted community to the centers.
UnitedHealth (UNH) Stock Drops 8% YTD: Should You Hold or Fold?
by Kaibalya Pravo Dey
As commercial business improves within the industry, UnitedHealth (UNH), with its diverse portfolio of offerings, is well-positioned to capitalize on the rising demand.
Humana's (HUM) CenterWell Expands in Louisiana With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell unit is likely to benefit from the opening of four new centers in the Baton Rouge and New Orleans areas in Louisiana, thus enhancing healthcare access for local seniors.
Humana's (HUM) CenterWell Sets Foot in Asheville With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell Senior Primary Care announces the opening of two centers in Asheville, thus enhancing access to high-quality healthcare services and driving revenues of the CenterWell unit.
Humana (HUM) Partners With UAB to Boost Care for MA Members
by Zacks Equity Research
Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.
Do Options Traders Know Something About Humana (HUM) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Humana (HUM) stock based on the movements in the options market lately.
Why Is Humana (HUM) Up 13.1% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Centene and Humana
by Zacks Equity Research
UnitedHealth, The Cigna, Centene and Humana have been highlighted in this Industry Outlook article.
Ensign Group (ENSG) Stock Down 2.4% Despite Q1 Earnings Beat
by Zacks Equity Research
Ensign Group (ENSG) expects revenues between $4.13 and $4.17 billion, the mid-point of which indicates an improvement of 11.3% from the 2023 figure.
4 HMO Stocks to Watch Amid Persistent Industry Challenges
by Debasmita Chatterjee
The Medical-HMO industry continues to witness an expanding customer base resulting from contract wins. However, high technology expenses and a shortage of medical personnel are a concern. UNH, CI, CNC and HUM are likely to navigate industry storms.
Cigna (CI) Q1 Earnings Beat on Client Wins in Evernorth Unit
by Zacks Equity Research
Cigna's (CI) Q1 results reflect strong organic growth in the Evernorth Health Services unit. It expects adjusted EPS of at least $28.40 for 2024, up from the earlier guidance of at least $28.25.
Investors Heavily Search Humana Inc. (HUM): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Humana (HUM). This makes it worthwhile to examine what the stock has in store.
Encompass Health (EHC) Stock Down Despite Q1 Earnings Beat
by Zacks Equity Research
Encompass Health (EHC) increases its guidance for net operating revenues, which is in the range of $5.25-$5.325 million for 2024.
Centene (CNC) Q1 Earnings Beat on Premiums, '24 EPS View Hiked
by Zacks Equity Research
Centene's (CNC) Q1 results reflect strength in the Commercial business line. Management currently expects adjusted EPS to be greater than $6.80 for 2024.
Molina Healthcare (MOH) Q1 Earnings Beat on Growing Membership
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results reflect strong premium revenue growth. It continues to estimate adjusted EPS at a minimum of $23.50 for 2024.
Humana (HUM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
by Zacks Equity Research
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
by Zacks Equity Research
Humana (HUM) bumps up individual Medicare Advantage membership growth guidance.
Humana (HUM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Humana (HUM) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 20.10% and 2.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Humana (HUM)
by Zacks Equity Research
Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Watch These 5 Medical Stocks for Q1 Earnings: Beat or Miss?
by Debasmita Chatterjee
Improved premiums resulting from membership growth, and higher patient admissions are expected to have driven the Q1 performance of HUM, MOH, UHS, EHC and CYH. An elevated operating expense level is likely to have dented growth prospects.